Levofloxacin efficacy in current surgical practice

Authors

  • O A Nazarchuk National Pirogov Memorial Medical University, Vinnytsia
  • Yu M Babina National Pirogov Memorial Medical University, Vinnytsia
  • D V Dmytriiev National Pirogov Memorial Medical University, Vinnytsia
  • V L Vitkovskiy National Pirogov Memorial Medical University, Vinnytsia

DOI:

https://doi.org/10.31636/prmd.v3i2.2

Keywords:

fluorchinolones, levofloxacin, treatment, infectious complications in surgery

Abstract

Results of domestic and international studies of the 3rd generation fluorchinolone Levofloxacin use in the prevention and treatment of inflammative diseases of the skin, soft tissues, intrabdominal and urogenital infectious complications is presented in the article. Analysis of clinical use of Levofloxacin in the treatment of many diseases indicates its high efficacy, absence of complications, low risk of resistance development, that allows to recommend it for the wide use in in medical practice.

Downloads

Download data is not yet available.

References

Weinrich M, Scheingraber S, Stremovskaia T, Schilling MK, Kees F, Pistorius GA. Liver tissue concentrations of levofloxacin after single intravenous administration of 500mg for antibiotic prophylaxis in liver surgery. International Journal of Antimicrobial Agents [Internet]. Elsevier BV; 2006 Sep;28(3):221–5. Available from: https://doi.org/10.1016/j.ijantimicag.2006.04.012

Paladino JA Is More Than One Quinolone needed in Clinical Practice? Annals of Pharmacotherapy [Internet]. SAGE Publications; 2001 Sep;35(9):1085–95. Available from: https://doi.org/10.1177/106002800103500906

Belousov YB, Mukhina MA. Clinical pharmacology of levofloxacin. Breast cancer. 2002; 10 (23): 1057–1062

Ushkalova EA, Zyryanov SK. Levofloxacin: benefit-risk ratio. Pharmateca, 2017; S2: 36–42.

Belotserkovsky BZ, Gelfand EB, Popov TV. Fluoroquinolones in the treatment of infections in surgery and intensive care: the place and effectiveness of levofloxacin. Comsilium medicum. 2007; 2 (6): 45–51

Pasechnikov JV, Mitchenko MV. The use of Leflocin in the treatment of acute pyelonephritis. The art of healing. 2005; 4 (20): 104– 107.

Yakovlev VP, Blatun LA, Mitish VA. Gradual use of levofloxacin in the treatment of patients with wound infection. Infections and antimicrobial therapy. 2004; 6 (1): 21–23.

Babushkina AV. Levofloxacin. Aspects of clinical application. Ukr. med. chasopis. 2010, April 10. Available from: http://www.uf.ua/wp_content/uploads/2016/05/6a4fccc34dbcd3b8fd79d1b0c73a 95de.pdf

Prokhorovich EA, Silina EG. Possibilities of clinical use of levofloxacin. Therapist. 2001; 9.

Croom KF, Goa KL. Levofloxacin. Drugs [Internet]. Springer Science and Business Media LLC; 2003;63(24):2769–802. Available from: https://doi.org/10.2165/00003495–200363240–00008

Instructions for the drug “Leflocin”. Available from: https://compendium.com.ua/dec/273857

Zueva AO, et al. Microbiological evaluation of fluoroquinolones II and III generations for the prevention and treatment of infectious complications of surgical operations. Bacteriology. 2017; 2(4): 50–54.

Padeiskaya En. Levofloxacin is a new drug of the group of fluoro-quinolones for the treatment of infectious diseases with wide indi-cations for use. Good Clinical Practice, 2008, 2: 80–95.

Chow AT, Chen A, Lattime H, Morgan n, Wong F, Fowler C, et al. Pen-etration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses. Journal of Clinical Pharmacy and Therapeutics [Internet]. Wiley; 2002 Apr;27(2):143–50. Available from: https://doi.org/10.1046/j.1365–2710.2002.00396.x

Kiesslich R, Will D, Hahn M. et al. Ceftriaxone versus Levofloxacin for antibiotic therapy in patients with acute сholangitis. Z. Gastro-enterol, 2003:41(1): 5–10.

Fomin PD, Et al. The use of levofloxacin in abdominal surgery. Ukrainian Chemotherapeutic Journal, 2010; 1: 2–3.

Buchanan R, Wareham D. Mechanisms of antibiotic resistance. Tu-torial Topics in Infection for the Combined Infection Training Pro-gramme, 2019, 347.

Sprandel KA, Schriever CA, Pendland SL, Quinn JP, Gotfried MH, Hackett S, et al. Pharmacokinetics and Pharmacodynamics of In-travenous Levofloxacin at 750 Milligrams and Various Doses of Metronidazole in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy [Internet]. American Society for Microbiol-ogy; 2004 Dec;48(12):4597–605. Available from: https://doi.org/10.1128/aac.48.12.4597–4605.2004

Davydova YuV, Limanskaya AU. The effectiveness of levofloxacin use in modern clinical practice. Women’s health, 2015, 8: 73–73.

Gelfand BR. Surgical infections of the skin and soft tissues. Russian national recommendations. 2nd ed. Moscow; 2015.

Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoro-quinolones. Clin. Infect. Dis. 2005; Vol. 41(Suppl. 2): 144–57.

Langtry HD, Lamb HM. Levofloxacin. Drugs [Internet]. Springer Science and Business Media LLC; 1998;56(3):487–515. Available from: https://doi.org/10.2165/00003495–199856030–00013

Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opinion on Drug Safety [Internet]. Informa Healthcare; 2013 May 7;12(4):497–505. Available from: https://doi.org/10.1517/14740338.2013.796362

Ефективність застосування левофлоксацину в сучасній хірургічній практиці

Published

2021-03-11

How to Cite

1.
Nazarchuk OA, Babina YM, Dmytriiev DV, Vitkovskiy VL. Levofloxacin efficacy in current surgical practice. prmd [Internet]. 2021 Mar. 11 [cited 2021 Jun. 13];3(2):11-6. Available from: https://perioperative.org.ua/index.php/prtmdc/article/view/48